VIATRIS INC. Income Tax Examination, Interest Expense
VIATRIS INC. (VTRS) reported Income Tax Examination, Interest Expense of $6.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationInterestExpense · last filed 2026-02-26
- VIATRIS INC. income tax examination, interest expense for fiscal 2025 was $6.20M.
- VIATRIS INC. income tax examination, interest expense for fiscal 2024 was -$300.00K.
- VIATRIS INC. income tax examination, interest expense for fiscal 2023 was -$300.00K, a 101.95% decline from fiscal 2022.
- VIATRIS INC. income tax examination, interest expense for fiscal 2022 was $15.40M, a 0.00% change from fiscal 2021.
| Period end | Income Tax Examination, Interest Expense 12 month | Income Tax Examination, Interest Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $6.20M 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$300.00K 10-K · filed 2025-02-27 | |
| 2023-12-31 | -$300.00K 10-K · filed 2026-02-26 | $15.40M 10-K · filed 2024-02-28 |
| 2022-12-31 | $15.40M 10-K · filed 2025-02-27 | $21.10M 10-K · filed 2023-02-27 |
| 2021-12-31 | $15.40M 10-K · filed 2026-02-26 | $18.50M 10-K · filed 2022-02-28 |
| 2020-12-31 | $21.10M 10-K · filed 2025-02-27 | $6.00M 10-K · filed 2021-03-01 |
| 2019-12-31 | $18.50M 10-K · filed 2024-02-28 | $6.00M 10-K · filed 2022-02-28 |
| 2018-12-31 | $6.00M 10-K · filed 2023-02-27 | -$35.20M 10-K · filed 2021-03-01 |
| 2017-12-31 | $35.20M 10-K · filed 2022-02-28 | |
| 2016-12-31 | -$18.30M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |